Sign up for Breaking News Email Alerts

Neuralstem News

Press Releases


Archives: Search / 2016 / 2015 / 2014 / 2013 / 2012

Coverage Highlights

8.1.14 Crain’s Detroit Business explores NSI-566 next steps with ALS P.I., Dr. Eva Feldman, and reviews additional indication, Alzheimer’s disease, following promising animal research.
7.30.14 The Wall Street Journal interviews President/CEO, Richard Garr, on patient-directed social media’s impact on trials. NSI-566/ALS patients have independently chosen to blog online.
November 2013 FORBES' feature quotes President/CEO Richard Garr extensively, on the differentiation and commercialization of Neuralstem’s proprietary cell technology.
11.20.13 FOX Medical Team's Beth Galvin continues her NSI-566/ALS coverage at Emory with a patient’s perspective segment. Phase I patients, Ted Harada and John Conley, are featured.
November-December 2013 Bethesda Magazine feature provides rich insights on Neuralstem’s “potential wonder drug aimed specifically at rebuilding the hippocampus”: NSI-189.
October 2013 Practical Neurology interviews Chairman and CSO Dr. Karl Johe and P.I. Dr. Eva Feldman about the NSI-566/ALS trials in “Decreasing Progression, Increasing Function.”
8.28.13 FOX News Detroit walks with NSI-566/ALS Phase I patient Ted Harada and P.I. Dr. Eva Feldman on the eve of the Phase II trial.
5.30.13 Bioscience Technology ALS P.I. Dr. Eva Feldman and Neuralstem’s President/CEO Richard Garr in a feature that explores data from six extraordinary ALS responders – “as rare as a red wolf.”
9.13.12 MIT's Technology Review reports on CELL SCI research showing “paralyzed rats walk again after stem cell transplant” of NSI-566, suggesting hope for treatment of spinal cord injury.

Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.

  • “After the Ice Bucket” - Neuralstem NSI-566/ALS Interview with Richard Garr

By Steve Usdin, Host, “BioCentury This Week,” October 19, 2014

Neuralstem's President and CEO, Richard Garr, sets out the company’s progress towards its goal of creating a neural stem cell therapy that will make ALS a manageable chronic disease and give patients a normal lifespan and good quality of life in this nearly six-minute TV segment, one of four on the future of ALS research produced by BioCentury in partnership with WUSA9, the CBS affiliate in Washington, D.C. Mr. Garr gives a thorough overview of NSI-566/ALS, including the neural stem cells; specially designed surgical devices used for the world’s first intraspinal injections; “rescue, nurture and integrate” treatment benefits, and Phase I final cohort three-year results from peer-reviewed, published data. NSI-566/ALS Phase II trials concluded final surgeries in July 2014.

View Segment

Privacy and Terms ©Neuralstem, Inc. 2016